Studies have suggested a strong "placebo effect" in the treatment of interstitial cystitis/bladder pain syndrome.
As body mass index increases, so does the risk of kidney and bladder cancers in men and stomach, ovarian, and colon cancers in women.
Study reveals a 2-fold greater likelihood of primary kidney and bladder cancer compared with men in the general population.
Current smoking and smoking cessation prior to diagnosis does not alter risk of recurrence or progression of non-muscle-invasive bladder cancer.
Study shows a significantly better 5-year cancer-specific survival rate compared with radical cystectomy.
Use of the drug reduced the risk of recurrence and cancer-related mortality in diabetic patients undergoing radical cystectomy.
Meta-analysis demonstrates a protective effect with high intake.
Their risk of death is 40% lower than that of patients who are not obese, study shows.
Venous thromboembolism is more likely to occur in patients with neurologic comorbidities and increased operative time.
It offers a survival benefit regardless of age, but is used less often in patients aged 70 years and older than in younger patients.
Radical cystectomy and chemo-radiation offer significantly better survival than other treatments or no treatment, study shows.
The 5-year recurrence-free and cancer-specific survival rates with robot-assisted radical cystectomy are 52.5% and 67.8%, respectively.
No increase found in the likelihood of any complication, re-operations, wound infection, and wound dehiscence.
Researchers coaxed human stem cells to develop into bladder cells.
Heat shock protein 105, high expression of which predicts better cancer-specific survival, may hold promise as a prognostic marker.
Alvimopan also was found to shorten hospital length of stay.